Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors-Reference-Cited by-同舟云学术

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors

Published:2017-09-14 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Manasa Justen,Varghese Vici,Pond Sergei L. Kosakovsky,Rhee Soo-Yon,Tzou Philip L.^ORCID,Fessel W. Jeffrey,Jang Karen S.^ORCID,White Elizabeth,Rögnvaldsson Thorsteinn,Katzenstein David A.,Shafer Robert W.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-11893-8.pdf

Reference45 articles.

1. Ali, A. et al. Molecular Basis for Drug Resistance in HIV-1 Protease. Viruses 2, 2509–2535, https://doi.org/10.3390/v2112509 (2010).

2. Barber, T. J. et al. Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother 67, 995–1000, https://doi.org/10.1093/jac/dkr569 (2012).

3. Dolling, D. I. et al. Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother 68, 2339–2343, https://doi.org/10.1093/jac/dkt199 (2013).

4. Mills, A. M. et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 23, 1679–1688, https://doi.org/10.1097/QAD.0b013e32832d7350 (2009).

5. El Bouzidi, K. et al. HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK. J Antimicrob Chemother 71, 3487–3494, https://doi.org/10.1093/jac/dkw343 (2016).

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV-1 envelope facilitates the development of protease inhibitor resistance through acquiring mutations associated with viral entry and immune escape;Frontiers in Microbiology;2024-04-18

2. A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance;Journal of Antimicrobial Chemotherapy;2023-12-28

3. A detailed characterisation of drug resistance during darunavir/ritonavir (DRV/r) monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance;2023-10-15

4. HIV-1 Evolutionary Dynamics under Nonsuppressive Antiretroviral Therapy;mBio;2022-06-28

5. HIV-1 evolutionary dynamics under non-suppressive antiretroviral therapy;2021-04-12